Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
Receptor, Epidermal Growth Factor
In EGFR mutated tumors resistant to gefitinib 250 mg/d, a switch to erlotinib 150 mg/d does not lead to responses in most patients. These findings are consistent with preclinical models, because the common mechanisms of TKI resistance (T790M and MET amplification) in vitro are not inhibited by clinically achievable doses of gefitinib or erlotinib. Alternative strategies to overcome TKI resistance must be evaluated.